<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758806</url>
  </required_header>
  <id_info>
    <org_study_id>432/2018-IK</org_study_id>
    <nct_id>NCT04758806</nct_id>
  </id_info>
  <brief_title>Fecal Microbial Transplantation in Severe Alcoholic Hepatitis</brief_title>
  <acronym>FMTH7</acronym>
  <official_title>Fecal Microbial Transplantation for Corticosteroids Non-responders and Non-eligible Patients With Severe Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. A subtype of Alcoholic hepatitis (AH), named severe alcoholic hepatitis (SAH) is&#xD;
           associated with high short-term mortality (J Hepatol, 2019)&#xD;
&#xD;
        2. The only SAH treatment option - corticosteroids (CS) - are often contraindicated or&#xD;
           ineffective (STOPAH Trial)&#xD;
&#xD;
        3. New treatment modalities for remaining patients are much needed&#xD;
&#xD;
        4. Fecal microbial transplantation (FMT) is one of the promising therapies&#xD;
&#xD;
        5. Investigators aimed to see if FMT improves survival in patients admitted with SAH, not&#xD;
           responding to-, or non-eligible for CS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  FMT via upper GI tract is provided to CS non-responders (NR) or non-eligible (NE) adult&#xD;
           patients hospitalized with SAH (determined by the Lille-model).&#xD;
&#xD;
        -  Modified version of the Sarin FMT protocol is used with microbiota material procured&#xD;
           from unrelated healthy donors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Eligible for the study are consecutive consenting adult patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-day</time_frame>
    <description>Overall mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90-day</time_frame>
    <description>Overall mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Overall mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute on chronic liver failure</measure>
    <time_frame>In-Hospital</time_frame>
    <description>Acute on chronic liver failure by European definition</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Fecal microbial transplantation from unrelated donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal microbial transplantation</intervention_name>
    <description>Procured faeces procured from unrelated donor</description>
    <arm_group_label>Fecal microbial transplantation from unrelated donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  consenting, adult&#xD;
&#xD;
          -  severe form of acute alcoholic hepatitis (SAH)&#xD;
&#xD;
          -  non-responder to corticosteroids according to the Lille model&#xD;
&#xD;
          -  patients with SAH not eligible for corticosteroids based on their contraindications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  presence of untreated large / high-risk / bleeding esophageal varices&#xD;
&#xD;
          -  too sick for any therapy / futility (chronic extrahepatic organ failures, no potential&#xD;
             for recovery, etc)&#xD;
&#xD;
          -  malignancy except for hepatocellular carcinoma in Milan criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubomir Skladany, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head Dept Internal Medicine F.D.Roosevelt Teaching Hospital Banska Bystrica Slovakia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lubomir Skladany, MD,PhD</last_name>
    <phone>+421905482997</phone>
    <email>lubomir.skladany@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Bystrianska, MD</last_name>
    <phone>+421917944393</phone>
    <email>naty2121@centrum.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>F.D.Roosevelt Teaching Hospital</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lubomir Skladany, MD, PhD</last_name>
      <phone>+421905482997</phone>
      <email>lubomir.skladany@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Natalia Bystrianska, MD</last_name>
      <phone>+421917944393</phone>
      <email>naty2121@centrum.sk</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Jancekova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janka Vnencakova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica</investigator_affiliation>
    <investigator_full_name>Ľubomír Skladaný MD, PhD</investigator_full_name>
    <investigator_title>Head, Department of Internal Medicine and HEGITO Liver Unit, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alcoholic hepatitis</keyword>
  <keyword>Nonresponders</keyword>
  <keyword>fecal microbial transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On request by institution of interest, e.g. on submission to medical journal / by editorial office; by auditing authority</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>First release of results is expected in 2021, final analysis in 2022</ipd_time_frame>
    <ipd_access_criteria>General Data Protection Regulation (GDPR) compliance Editorial office approved member Auditing authority Authors, meta analysis / systematic review</ipd_access_criteria>
    <ipd_url>http://www.fnspfdr.sk</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

